Characterization of PTZ-induced seizure susceptibility in a down syndrome mouse model that overexpresses CSTB

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Brault, Véronique ^a   Martin, Benoît ^b,c   Costet, Nathalie ^b,c   Bizot, Jean Charles ^d   Hérault, Yann ^a,e,f  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d Key Obs SAS   (France)

^e CNRS   (France)

^f INSTITUT CLINIQUE DE LA SOURIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PENTETRAZOLE; CSTB PROTEIN, MOUSE; CYSTATIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIA; BRAIN; BRAIN ATROPHY; CEREBELLUM; CLONIC SEIZURE; CONTROLLED STUDY; CSTB GENE; DISEASE PREDISPOSITION; DOWN SYNDROME; ELECTROENCEPHALOGRAM; GENE; GENE DOSAGE; GENE OVEREXPRESSION; HOMOLOGOUS RECOMBINATION; LIVER; LOCOMOTION; MOUSE; MYOCLONUS EPILEPSY; NONHUMAN; TANDEM REPEAT; TETRASOMY; TRANSGENIC MOUSE; TRISOMY; ANIMAL; ATROPHY; C57BL MOUSE; DISEASE MODEL; ELECTROPHYSIOLOGY; ENZYMOLOGY; GENE DUPLICATION; GENETICS; GENOTYPE; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEIZURE;

ANIMALS; ATROPHY; BRAIN; CYSTATIN B; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; DOWN SYNDROME; ELECTROPHYSIOLOGICAL PHENOMENA; GENE DUPLICATION; GENOTYPE; HUMANS; LIVER; LOCOMOTION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PENTYLENETETRAZOLE; SEIZURES; TETRASOMY;

EID: 82355183178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027845     Document Type: Article

References (94)

1. Dierssen M, Herault Y, Estivill X, (2009) Aneuploidy: From a Physiological Mechanism of Variance to Down Syndrome. Physiological Reviews 89: 887-920.
2. Sylvester PE, (1983) The hippocampus in downs-syndrome. Journal of Mental Deficiency Research 27: 227-236.
3. Aylward EH, Li Q, Honeycutt NA, Warren AC, Pulsifer MB, et al. (1999) MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia. American Journal of Psychiatry 156: 564-568.
4. Pinter JD, Brown WE, Eliez S, Schmitt JE, Capone GT, et al. (2001) Amygdala and hippocampal volumes in children with Down syndrome: A high-resolution MRI study. Neurology 56: 972-974.
5. Krasuski JS, Alexander GE, Horwitz B, Rapoport SI, Schapiro MB, (2002) Relation of medial temporal lobe volumes to age and memory function in nondemented adults with Down's syndrome: Implications for the prodromal phase of Alzheimer's disease. American Journal of Psychiatry 159: 74-81.
6. Gardiner K, Fortna A, Bechtel L, Davisson MT, (2003) Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 318: 137-147.
7. Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, et al. (1995) A Mouse model for down-syndrome exhibits learning and behavior deficits. Nature Genetics 11: 177-184.
8. Salehi A, Faizit M, Belichenko PV, Mobley WC, (2007) Using mouse modets to explore genotype-phenotyperelationship in Down syndrome. Mental Retardation and Developmental Disabilities Research Reviews 13: 207-214.
9. Gardiner KJ, (2010) Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends in Pharmacological Sciences 31: 66-73.
10. Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, et al. (2007) Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nature Neuroscience 10: 411-413.
11. Rueda N, Florez J, Cue CM, (2008) Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in ts65dn mice, a model for down's syndrome. Methods and Findings in Experimental and Clinical Pharmacology 30: 92-92.
12. Olsen RW, (1981) The gaba postsynaptic membrane receptor-ionophore complex- site of action of convulsant and anticonvulsant drugs. Molecular and Cellular Biochemistry 39: 261-279.
13. Ramanjaneyulu R, Ticku MK, (1984) Interactions of pentamethylenetetrazole and tetrazole analogs with the picrotoxinin site of the benzodiazepine-gaba receptor-ionophore complex. European Journal of Pharmacology 98: 337-345.
14. Veall RM, (1974) Prevalence of epilepsy among mongols related to age. Journal of Mental Deficiency Research 18: 99-106.
15. McVicker RW, Shanks OEP, McClelland RJ, (1994) Prevalence and associated features of epilepsy in adults with downs-syndrome. British Journal of Psychiatry 164: 528-532.
16. Tangye SR, (1979) Eeg and incidence of epilepsy in downs-syndrome. Journal of Mental Deficiency Research 23: 17-24.
17. Pueschel SM, Louis S, McKnight P, (1991) Seizure disorders in down-syndrome. Archives of Neurology 48: 318-320.
18. Sultan M, Piccini I, Balzereit D, Herwig R, Saran NG, et al. (2007) Gene expression variation in 'Down syndrome' mice allows prioritization of candidate genes. Genome Biology 8.
19. Virtaneva K, Damato E, Miao IM, Koskiniemi M, Norio R, et al. (1997) Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nature Genetics 15: 393-396.
20. Lalioti MD, Scott HS, Buresi C, Rossier C, Bottani A, et al. (1997) Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 386: 847-851.
21. Lafreniere RG, Rochefort DL, Chretien N, Rommens JM, Cochius JI, et al. (1997) Unstable insertion in the 5′ flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1. Nature Genetics 15: 298-302.
22. Moller JC, Hamer HM, Oertel WH, Rosenow F, (2001) Late-onset myoclonic epilepsy in Down's syndrome (LOMEDS). Seizure-European Journal of Epilepsy 10: 303-305.
23. Osawa M, Kaneko M, Horiuchi H, Kitano T, Kawamoto Y, et al. (2003) Evolution of the cystatin B gene: implications for the origin of its variable dodecamer tandem repeat in humans. Genomics 81: 78-84.
24. Alakurtti K, Weber E, Rinne R, Theil G, de Haan GJ, et al. (2005) Loss of lysosomal association of cystatin B proteins representing progressive myoclonus epilepsy, EPM1, mutations. European Journal of Human Genetics 13: 208-215.
25. Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL, et al. (1998) Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nature Genetics 20: 251-258.
26. Franceschetti S, Sancini G, Buzzi A, Zucchini S, Paradiso B, et al. (2007) A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression. Neurobiology of Disease 25: 675-685.
27. D'Amato E, Kokaia Z, Nanobashvili A, Reeben M, Lehesjoki AE, et al. (2000) Seizures induce widespread upregulation of cystatin B, the gene mutated in progressive myoclonus epilepsy, in rat forebrain neurons. European Journal of Neuroscience 12: 1687-1695.
28. Bjarnadottir M, Nilsson C, Lindstrom V, Westman A, Davidsson P, et al. (2001) The cerebral hemorrhage-producing cystatin C variant (L68Q) in extracellular fluids. Amyloid-Journal of Protein Folding Disorders 8: 1-10.
29. Ceru S, Layfield R, Zavasnik-Bergant T, Repnik U, Kopitar-Jerala N, et al. (2010) Intracellular aggregation of human stefin B: confocal and electron microscopy study. Biology of the Cell 102: 319-334.
30. Cipollini E, Riccio M, Di Giaimo R, Dal Piaz F, Pulice G, et al. (2008) Cystatin B and its EPM1 mutants are polymeric and aggregate prone in vivo. Biochimica Et Biophysica Acta-Molecular Cell Research 1783: 312-322.
31. Brault V, Pereira P, Duchon A, Herault Y, (2006) Modeling chromosomes in mouse to explore the function of genes, genomic disorders, and chromosomal organization. Plos Genetics 2: 911-919.
32. Zheng BH, Mills AA, Bradley A, (1999) A system for rapid generation of coat color-tagged knockouts and defined chromosomal rearrangements in mice. Nucleic Acids Research 27: 2354-2360.
33. Magin T, McWhir J, Melton D, (1992) A new mouse embryonic stem cell line with good germ line contribution and gene targeting frequency. Nucleic Acids Res 20: 3795-3796.
34. Wilson WA, Escueta AV, (1974) Common synaptic effects of pentylenetetrazol and penicillin. Brain Research 72: 168-171.
35. FitzPatrick DR, Ramsay J, McGill NI, Shade M, Carothers AD, et al. (2002) Transcriptome analysis of human autosomal trisomy. Human Molecular Genetics 11: 3249-3256.
36. Mao R, Zielke CL, Zielke HR, Pevsner J, (2003) Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. Genomics 81: 457-467.
37. Yahya-Graison EA, Aubert J, Dauphinot L, Rivals I, Prieur M, et al. (2007) Classification of human chromosome 21 gene-expression variations in down syndrome: Impact on disease phenotypes. American Journal of Human Genetics 81: 475-491.
38. Conti A, Fabbrini F, D'Agostino P, Negri R, Greco D, et al. (2007) Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. Bmc Genomics 8.
39. Epstein CJ, Avraham KB, Lovett M, Smith S, Elroystein O, et al. (1987) Transgenic mice with increased cu/zn-superoxide dismutase activity- animal-model of dosage effects in down-syndrome. Proceedings of the National Academy of Sciences of the United States of America 84: 8044-8048.
40. Elson A, Levanon D, Weiss Y, Groner Y, (1994) Overexpression of liver-type phosphofructokinase (pfkl) in transgenic-pfkl mice- implication for gene dosage in trisomy-21. Biochemical Journal 299: 409-415.
41. Gerlai R, Roder J, (1993) Female-specific hyperactivity in s100-beta transgenic mice does not habituate in open-field. Behavioural Brain Research 59: 119-124.
42. Gerlai R, Roder J, (1996) Spatial and nonspatial learning in mice: Effects of S100 beta overexpression and age. Neurobiology of Learning and Memory 66: 143-154.
43. Sumarsono SH, Wilson TJ, Tymms MJ, Venter DJ, Corrick CM, et al. (1996) Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice. Nature 379: 534-537.
44. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing v717f beta-amyloid precursor protein. Nature 373: 523-527.
45. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. (1996) Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
46. SturchlerPierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proceedings of the National Academy of Sciences of the United States of America 94: 13287-13292.
47. Moechars D, Gilis M, Kuiperi C, Laenen I, Van Leuven F, (1998) Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs. Neuroreport 9: 3561-3564.
48. Ema M, Ikegami S, Hosoya T, Mimura J, Ohtani H, et al. (1999) Mild impairment of learning and memory in mice overexpressing the mSim2 gene located on chromosome 16: an animal model of Down's syndrome. Human Molecular Genetics 8: 1409-1415.
49. Martinez-Cue C, Baamonde C, Lumbreras MA, Vallina IF, Dierssen M, et al. (1999) A murine model for Down syndrome shows reduced responsiveness to pain. Neuroreport 10: 1119-1122.
50. Pennacchio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, et al. (1996) Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 271: 1731-1734.
51. Marcell MM, Armstrong V, (1982) Auditory and visual sequential memory of down syndrome and nonretarded-children. American Journal of Mental Deficiency 87: 86-95.
52. Vicari S, Marotta L, Menghini D, Carlesimo GA, (2000) Working memory and speech fluency in subjects with Down syndrome. Journal of Intellectual Disability Research 44: 1217.
53. Pennington BF, Moon J, Edgin J, Stedron J, Nadel L, (2003) The neuropsychology of Down syndrome: Evidence for hippocampal dysfunction. Child Development 74: 75-93.
54. Clark D, Wilson GN, (2003) Behavioral assessment of children with Down syndrome using the Reiss psychopathology scale. American Journal of Medical Genetics Part A 118A: 210-216.
55. Nadel L, (2003) Down's syndrome: a genetic disorder in biobehavioral perspective. Genes Brain and Behavior 2: 156-166.
56. Hodapp RM, Dykens EM, (2005) Measuring behavior in genetic disorders of mental retardation. Mental Retardation and Developmental Disabilities Research Reviews 11: 340-346.
57. Dierssen M, (2003) Special interest section- Down's syndrome: postgenomic approaches to neurobiological problems. Genes Brain and Behavior 2: 152-155.
58. Insausti AM, Megias M, Crespo D, Cruz-Orive LM, Dierssen M, et al. (1998) Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of down syndrome. Neuroscience Letters 253: 175-178.
59. Baxter LL, Moran TH, Richtsmeier JT, Troncoso J, Reeves RH, (2000) Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Human Molecular Genetics 9: 195-202.
60. Kurt MA, Davies DC, Kidd M, Dierssen M, Florez J, (2000) Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. Brain Research 858: 191-197.
61. Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, et al. (2004) Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. Journal of Comparative Neurology 480: 281-298.
62. Belichenko PV, Kleschevnikov AM, Salehi A, Epstein CJ, Mobley WC, (2007) Synaptic and cognitive abnormalities in mouse models of down syndrome: Exploring genotype-phenotype relationships. Journal of Comparative Neurology 504: 329-345.
63. Belichenko PV, Klescrevnikov AM, Masliah E, Wu CB, Takimoto-Kimura R, et al. (2009) Excitatory-Inhibitory Relationship in the Fascia Dentata in the Ts65Dn Mouse Model of Down Syndrome. Journal of Comparative Neurology 512: 453-466.
64. Bespalova IN, Adkins S, Pranzatelli M, Burmeister M, (1997) Novel cystatin B mutation and diagnostic PCR assay in an Unverricht-Lundborg progressive myoclonus epilepsy patient. American Journal of Medical Genetics 74: 467-471.
65. Lalioti MD, Mirotsou M, Buresi C, Peitsch MC, Rossier C, et al. (1997) Identification of mutations in Cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1). American Journal of Human Genetics 60: 342-351.
66. Kagitani-Shimono K, Imai K, Okamoto N, Ono J, Okada S, (2002) Unverricht-Lundborg disease with cystatin B gene abnormalities. Pediatric Neurology 26: 55-60.
67. Joensuu T, Kuronen M, Alakurtti K, Tegelberg S, Hakala P, et al. (2007) Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients. European Journal of Human Genetics 15: 185-193.
68. Jarvinen M, Rinne A, (1982) Human spleen cysteine-proteinase inhibitor- purification, fractionation into isoelectric variants and some properties of the variants. Biochimica Et Biophysica Acta 708: 210-217.
69. Turk V, Bode W, (1991) The cystatins- protein inhibitors of cysteine proteinases. Febs Letters 285: 213-219.
70. Ritonja A, Machleidt W, Barrett AJ, (1985) Amino-acid sequence of the intracellular cysteine proteinase-inhibitor cystatin-b from human-liver. Biochemical and Biophysical Research Communications 131: 1187-1192.
71. Jerala R, Trstenjak M, Lenarcic B, Turk V, (1988) Cloning a synthetic gene for human stefin-b and its expression in escherichia-coli. Febs Letters 239: 41-44.
72. Green GDJ, Kembhavi AA, Davies ME, Barrett AJ, (1984) Cystatin-like cysteine proteinase-inhibitors from human-liver. Biochemical Journal 218: 939-946.
73. Abrahamson M, Barrett AJ, Salvesen G, Grubb A, (1986) Isolation of 6 cysteine proteinase-inhibitors from human-urine- their physicochemical and enzyme kinetic-properties and concentrations in biological-fluids. Journal of Biological Chemistry 261: 1282-1289.
74. Bromme D, Rinne R, Kirschke H, (1991) Tight-binding inhibition of cathepsin-s by cystatins. Biomedica Biochimica Acta 50: 631-635.
75. Di Giaimo R, Riccio M, Santi S, Galleotti C, Ambrosetti DC, et al. (2002) New insights into the molecular basis of progressive myoclonus epilepsy: a multiprotein complex with cystatin B. Human Molecular Genetics 11: 2941-2950.
76. Altafaj X, Dierssen M, Baamonde C, Marti E, Visa J, et al. (2001) Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Human Molecular Genetics 10: 1915-1923.
77. Fotaki V, Dierssen M, Alcantara S, Martinez S, Marti E, et al. (2002) Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Molecular and Cellular Biology 22: 6636-6647.
78. Moulard B, Genton P, Grid D, Jeanpierre M, Ouazzani R, et al. (2002) Haplotype study of West European and North African Unverricht-Lundborg chromosomes: evidence for a few founder mutations. Human Genetics 111: 255-262.
79. Ceru S, Rabzelj S, Kopitar-Jerala N, Turk V, Zerovnik E, (2005) Protein aggregation as a possible cause for pathology in a subset of familial Unverricht-Lundborg disease. Medical Hypotheses 64: 955-959.
80. Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, et al. (2004) Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. Journal of Neuroscience 24: 8153-8160.
81. Patil N, Cox DR, Bhat D, Faham M, Myers RM, et al. (1995) A potassium channel mutation in weaver mice implicates membrane excitability in granule cell-differentiation. Nature Genetics 11: 126-129.
82. Hallmann K, Durner M, Sander T, Steinlein OK, (2000) Mutation analysis of the inwardly rectifying K+ channels KCNJ6 (GIRK2) and KCNJ3 (GIRK1) in juvenile myoclonic epilepsy. American Journal of Medical Genetics 96: 8-11.
83. Chioza B, Osei-Lah A, Wilkie H, Nashef L, McCormick D, et al. (2002) Suggestive evidence for association of two potassium channel genes with different idiopathic generalised epilepsy syndromes. Epilepsy Research 52: 107-116.
84. Yamakawa K, Huo YK, Haendel MA, Hubert R, Chen XN, et al. (1998) DSCAM: a novel member of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development of the nervous system. Human Molecular Genetics 7: 227-237.
85. Hattori D, Demir E, Kim HW, Viragh E, Zipursky SL, et al. (2007) Dscam diversity is essential for neuronal wiring and self-recognition. Nature 449: 223-U226.
86. McPherson PS, Garcia EP, Slepnev VI, David C, Zhang XM, et al. (1996) A presynaptic inositol-5-phosphatase. Nature 379: 353-357.
87. Voronov SV, Frere SG, Giovedi S, Pollina EA, Borel C, et al. (2008) Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndrome. Proceedings of the National Academy of Sciences of the United States of America 105: 9415-9420.
88. Raff MC, Miller RH, Noble M, (1983) A glial progenitor-cell that develops invitro into an astrocyte or an oligodendrocyte depending on culture-medium. Nature 303: 390-396.
89. Buffo A, Vosko MR, Erturk D, Hamann GF, Jucker M, et al. (2005) Expression pattern of the transcription factor Olig2 in response to brain injuries: Implications for neuronal repair. Proceedings of the National Academy of Sciences of the United States of America 102: 18183-18188.
90. Higuchi M, Stefan M, Single FN, Hartner J, Rozov A, et al. (2000) Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature 406: 78-81.
91. Xiao F, Chen D, Lu Y, Xiao Z, Guan LF, et al. (2009) Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy. Brain Research 1255: 180-189.
92. Lyle R, Gehrig C, Neergaard-Henrichsen C, Deutsch S, Antonarakis SE, (2004) Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. Genome Research 14: 1268-1274.
93. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25: 402-408.
94. Crawley JN, (2008) Behavioral phenotyping strategies for mutant mice. Neuron 57: 809-818.